AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

Naturally, Cigna's bulked-up service offerings should allow it to cross-sell traditional PBM and specialty pharmacy services into its managed-care client set and vice versa, opening up new profit ...

Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program ...

AustinPx, a contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement for orally delivered small molecule drugs, today announced the introduction of the ...

Aqemia announces it is broadening and accelerating its computational platform to target RNAs using its physics-enabled ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Mick Hitchcock, Ph.D., appointed Interim Chief Executive Officer Biomea preparing icovamenib for late-stage clinical development Multiple ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...

Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter ...

The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...

BOC Sciences adds to its participation agenda the prestigious Drug Discovery Chemistry 2025 Conference (April 14-17, 2025), which will be a hybrid event taking place in San Diego, CA, and will offer ...

While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...